Alexion Pharma (ALXN) Tops Q1 EPS by 20c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Reports First Quarter 2019 Results
April 25, 2019 6:30 AM EDT1Q19 total revenues of $1,140.4 million, a 23 percent increase over 1Q18 and a 26 percent volume increase 1Q19 GAAP diluted EPS of $2.61; non-GAAP diluted EPS of $2.39 Strong U.S. launch underway for ULTOMIRIS® (ravulizumab-cwvz) in adults with paroxysmal noctural hemoglobinuria (PNH); PNH applications under review in EU and Japan; U.S. filing submitted for atypical hemolytic uremic syndrome (aHUS) SOLIRIS® (eculizumab) for neuromyelitis optica spectrum disorder (NMOSD) granted Priority Review by U.S. FDA with action date of June 28, 2019; EU and Japanese applications under review... More
